Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158536 | 0.91 | NAMPT (0.84) | NAMPT | |
| SCHEMBL12468188 | 0.91 | NAMPT (0.83) | NAMPT | |
| SCHEMBL16858029 | 0.90 | NAMPT (1.00) | NAMPT | |
| SCHEMBL12467983 | 0.90 | NAMPT (0.80) | NAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16108651 | 0.89 | NAMPT (0.85) | NAMPTCYP2C9 | |
| SCHEMBL12466848 | 0.88 | NAMPT (0.84) | NAMPTCYP2C9 | |
| SCHEMBL173694 | 0.88 | NAMPT (0.79) | NAMPT | |
| SCHEMBL16108274 | 0.88 | NAMPT (0.79) | NAMPTCYP2C9 | |
| SCHEMBL16108262 | 0.88 | NAMPT (0.78) | NAMPT | |
| SCHEMBL30167886 | 0.88 | NAMPT (0.78) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| WO-2013170191-A1 | METHODS OF USING ANTAGONISTS OF NAD BIOSYNTHESIS FROM NICOTINAMIDE | GENENTECH, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP3A4 2444/4885CYP2C9 2180/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP3A4 1137/4885CYP2C9 725/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP3A4 2444/4885CYP2C9 2180/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP3A4 1137/4885CYP2C9 725/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP3A4 1137/4885CYP2C9 725/4885 |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP3A4 1137/4885CYP2C9 725/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885CYP3A4 2444/4885CYP2C9 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.